Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study
Table 5
Predictors of liver deterioration during COVID-19.
Variables
Cirrhosis
Child-Pugha score deterioration
MELDb score deterioration
During COVID ()
During COVID ()
Univariate analysis
Univariate analysis
OR (95% CI)
OR (95% CI)
Age
0.96 (0.9-1.02)
0.2
0.97 (0.9-1.03)
0.4
F/M
3.3 (0.8-14.1)
0.1
2.3 (0.7-7.9)
0.2
Etiology of cirrhosis
Alcohol
0.6 (0.1-3.1)
0.5
0.97 (0.3-3.6)
0.97
Nonalcoholic steatohepatitis
0.3 (0.1-1.4)
0.1
0.5 (0.12-2.4)
0.4
Hepatitis C
0.2 (0.3-1.4)
0.1
0.34 (0.05-2.3)
0.3
Hepatitis B
—
0.5 (0.04-5.9)
0.6
Alfa-1-antitrypsin deficiency
—
0.000
1
COVID-19-related hospitalization
0.1 (0.01-0.83)
0.03
0 (0)
0.998
COVID-19-related intensive care
0.3 (0.05-1.2)
0.09
0.9 (1.2-4.8)
0.9
COVID-19-related mortality
0.3 (0.06-1.1)
0.07
0.04 (0.008-0.2)
0.0001
Deterioration of cirrhosis was defined as requirement of aChild-Pugh score (A-B, A-C, and B-C), increase in b during hospitalization for COVID-19, or/and developed clinical manifestations such as jaundice, ascites, and varicose veins.
